Abstract: The purpose of the present invention is to provide novel compounds having ACC2 selective inhibitory activity. In addition, the present invention provides a pharmaceutical composition comprising the compound. A compound of Formula: or its pharmaceutically acceptable salt, wherein, R1 is substituted or unsubstituted fused aromatic heterocyclyl represented by Formula: wherein, ring B is 5-membered ring, ring C is 6-membered ring; ring A is substituted or unsubstituted non-aromatic carbocycle or the like; -L1- is —O—(CR6R7)m- or the like; -L2- is —O—(CR6R7)n- or the like; each R6 is independently hydrogen or the like; each R7 is independently hydrogen or the like; each m is independently an integer of 0, 1, 2 or 3; each n is independently an integer of 1, 2 or 3; R2 is substituted or unsubstituted alkyl; R3 is hydrogen or substituted or unsubstituted alkyl; R4 is substituted or unsubstituted alkylcarbonyl or the like.

Abstract: The present invention is the following Amphotericin B derivative: wherein each symbol is defined in description. The compound of the present invention has 16th position (X) is urea structure, cyclic structure, hydroxyalkyl or substituted monoalkylcarbamoyl. The compound of the present invention has antifungal activity.

Abstract: Provided is a compound which is useful as an AMPK activator. The compound is represented by formula: wherein the symbols are defined in the specification.

Abstract: The purpose of the present invention is to provide novel miR-143 derivatives described herein that can be used as oligonucleotide therapeutics.

Abstract: The present invention provides the following compounds having anti-viral activity. A1 is CR1AR1B, S or O; A2 is CR2AR2B, S or O; A3 is CR3AR3B, S or O; A4 is CR4AR4B, S or O; the number of hetero atoms among atoms constituting the ring which consists of A1, A2, A3, A4, nitrogen atom adjacent to A1 and carbon atom adjacent to A1, is 1 or 2; R1A and R1B are each independently hydrogen, halogen, alkyl, or the like; R2A and R2B are each independently hydrogen, halogen, alkyl, or the like; R3A and R3B are each independently hydrogen, halogen, alkyl, or the like; R4A and R4B are each independently hydrogen, halogen, alkyl, or the like; R3A and R3B may be taken together to form non-aromatic carbocycle or non-aromatic heterocycle; X is CH2, S or O; R1 is each independently halogen, hydroxy, or the like; m is any integer of 0 to 2; and n is any integer of 1 to 2.

Abstract: The present invention is the following Amphotericin B derivative: wherein each symbol is defined in description. The compound of the present invention has 16th position (X) is urea structure, cyclic structure, hydroxyalkyl or substituted monoalkylcarbamoyl. The compound of the present invention has antifungal activity.

Abstract: Provided is a monoclonal antibody or a fragment thereof that selectively inhibits the enzymatic activity of vascular endothelial lipase and pharmaceutical compositions containing the same as an active ingredient useful for the treatment of arteriosclerosis or metabolic syndrome.

Abstract: The purpose of the present invention is to provide novel compounds having ACC2 selective inhibitory activity. In addition, the present invention provides a pharmaceutical composition comprising the compound. A compound of Formula: or its pharmaceutically acceptable salt, wherein, R1 is substituted or unsubstituted fused aromatic heterocyclyl represented by Formula: wherein, ring B is 5-membered ring, ring C is 6-membered ring; ring A is substituted or unsubstituted non-aromatic carbocycle or the like; —L1— is —O—(CR6R7)m— or the like; —L2— is —O—(CR6R7)n— or the like; each R6 is independently hydrogen or the like; each R7 is independently hydrogen or the like; each m is independently an integer of 0, 1, 2 or 3; each n is independently an integer of 1, 2 or 3; R2 is substituted or unsubstituted alkyl; R3 is hydrogen or substituted or unsubstituted alkyl; R4 is substituted or unsubstituted alkylcarbonyl or the like.

Abstract: The present invention provides a pharmaceutical composition for cancer treatment comprising an antibody against CCR8.

Abstract: Provided is a compound which is useful as an AMPK activator. The compound is represented by formula: wherein the symbols are defined in the specification.

Abstract: The present invention relates to a compound represented by Formula (I): wherein -L- is —C(?X)—, or the like, —Z— is —NR5—, or the like, —ZA— is —NR5A—, or the like, —W— is —C(R8R9)n-, —WA— is —C(R3R4)m-, B is substituted or unsubstituted aromatic carbocyclyl, or the like, Y is a bond, or the like, the ring C is a substituted or unsubstituted aromatic heterocycle, or the like, R2 is a hydrogen atom, or the like, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising thereof.

Abstract: The present invention relates to a novel compound having an antiviral effect, more specifically, a pyridone derivative having HIV integrase inhibitory activity, and a medicament containing the same, in particular, an anti-HIV agent. The compound of the present invention has integrase inhibitory activity and/or cell proliferation inhibitory activity against viruses, in particular, HIV and drug-resistant strains thereof. Thus, the compound is useful in preventing or treating various diseases, viral infections (for example, AIDS), and the like in which integrase participates.

Abstract: The present invention provides a compound having antiviral effects, particularly having growth inhibitory activity on influenza viruses, a preferred example of the compound being a substituted 3-hydroxy-4-pyridone derivative prodrug having cap-dependent endonuclease inhibitory activity.

Abstract: The present invention provides a compound of formula (1), wherein R1, R2, R3, R4a, R4b, R5a and R5b are as defined in the description, which has an autotaxin inhibitory activity, a pharmaceutical composition comprising the compound as an active ingredient, and a method of prevention or treatment of a disease involving autotaxin, which is characterized by administering the compound.

Abstract: A compound according to any one of formula (Ia) to (Ic), or its pharmaceutically acceptable salt: wherein R1, R2, R3, R4a, R4c, R5 are as defined in the description.

Abstract: The compounds of the subject invention are related to 2-substituted cephem compounds, which have a wide antimicrobial spectrum, in particular exhibit potent antimicrobial activity against beta-lactamase producing Gram negative bacteria, and pharmaceutical compositions comprising the same.

Abstract: The present invention provides a process for preparation of the compound of formula (VI), wherein each symbol is as defined in the specification, without using any intermediate compound showing mutagenicity. The process comprises salt formation of the intermediate compound of formula (I) with acid to enable optical resolution to isolate the intermediate compound of formula (II) in a stereo-selective manner.

Abstract: The present invention relates to a compound represented by Formula (I): wherein -L- is —C(?X)—, or the like, —Z— is —NR5—, or the like, —ZA— is —NR5A—, or the like, —W— is —C(R8R9)n-, —WA— is —C(R3R4)m-, B is substituted or unsubstituted aromatic carbocyclyl, or the like, Y is a bond, or the like, the ring C is a substituted or unsubstituted aromatic heterocycle, or the like, R2 is a hydrogen atom, or the like, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising thereof.

Abstract: The present invention provides a novel compound having an antiviral activity, in particular, an HIV replication inhibiting activity, as well as a pharmaceutical composition, in particular, an anti-HIV agent. wherein ring A is substituted or unsubstituted carbocycle or substituted or unsubstituted heterocycle; R1 is substituted or unsubstituted alkyl etc.; R2 is substituted or unsubstituted alkyloxy etc.; n is 1 or 2; R3 is substituted or unsubstituted carbocyclyl or substituted or unsubstituted heterocyclyl; R4 is a hydrogen atom etc.; R6 is substituted or unsubstituted alkyl etc.

Abstract: The present invention relates to a compound represented by Formula (I): wherein X is, for example, C(?O); Z is, for example, C(?O); L is, for example, a single bond; A is, for example, aromatic carbocycle; R is, for example, R6 or B; R2 is, for example, hydrogen; R3 is, for example, substituted or unsubstituted alkyl; R4a is, for example, hydrogen; R4b is, for example, hydrogen; R5 is, for example, halogen; R6 is, for example, halogen; R7a is, for example, hydrogen; R7b is, for example, hydrogen; R8 is, for example, hydrogen; R9 is, for example, hydrogen; m is 0 to 5; n is 0 to 5; and p is 1 to 6, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same.